Investigational Drug Information for PF-05175157
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug PF-05175157?
PF-05175157 is an investigational drug.
There have been 13 clinical trials for PF-05175157.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2014.
The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Overweight. The leading clinical trial sponsors are Pfizer and [disabled in preview].
There are four US patents protecting this investigational drug and forty-eight international patents.
Summary for PF-05175157
| US Patents | 4 |
| International Patents | 48 |
| US Patent Applications | 11 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2014-04-01) |
| Vendors | 33 |
Recent Clinical Trials for PF-05175157
| Title | Sponsor | Phase |
|---|---|---|
| Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris | Pfizer | Phase 2 |
| A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin | Pfizer | Phase 2 |
| A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin | Pfizer | Phase 2 |
Clinical Trial Summary for PF-05175157
Top disease conditions for PF-05175157
Top clinical trial sponsors for PF-05175157
US Patents for PF-05175157
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PF-05175157 | See Plans and Pricing | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| PF-05175157 | See Plans and Pricing | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| PF-05175157 | See Plans and Pricing | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| PF-05175157 | See Plans and Pricing | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | Pfizer Inc. (New York, NY) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-05175157
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PF-05175157 | African Regional IP Organization (ARIPO) | AP3283 | 2029-11-10 | See Plans and Pricing |
| PF-05175157 | Argentina | AR078944 | 2029-11-10 | See Plans and Pricing |
| PF-05175157 | Australia | AU2010317501 | 2029-11-10 | See Plans and Pricing |
| PF-05175157 | Brazil | BR112012011072 | 2029-11-10 | See Plans and Pricing |
| PF-05175157 | Canada | CA2778886 | 2029-11-10 | See Plans and Pricing |
| PF-05175157 | Chile | CL2012000999 | 2029-11-10 | See Plans and Pricing |
| PF-05175157 | China | CN102695708 | 2029-11-10 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
